Navigation Links
Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
Date:10/27/2011

SAN DIEGO, Oct. 27, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced positive results from a study in patients with type 1 diabetes that receive their insulin therapy via pumps. The Phase 1b study was conducted as a randomized, double-blind, crossover design, to determine insulin pharmacokinetics, glucodynamics, safety and tolerability of rHuPH20 (recombinant human hyaluronidase) as a single injection prior to the start of three days of NovoLog® insulin aspart pump infusion therapy. The data demonstrated that pre-administration of 150 units of rHuPH20 (approximately 1.3 micrograms of enzyme) led to consistent insulin exposure over the infusion set life and superior glucose control following meals.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

"The more consistent physiologic insulin absorption profiles observed over infusion set life in these studies are promising," said Daniel Einhorn, MD, FACP, FACE, Clinical Professor of Medicine at the University of California, San Diego and Medical Director of the Scripps Whittier Diabetes Institute.  "Reducing the variability of insulin absorption should provide patients on insulin pump therapy improved ability to control diabetes while reducing risks of hypoglycemia."

Clinical Study and Results

The study compared pharmacokinetic (PK) and glucodynamic (GD) responses during euglycemic glucose clamp studies and responses to standardized mixed meal challenges administered in conjunction with individualized doses of insulin aspart, th
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
2. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
3. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
4. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
5. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
6. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
7. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
8. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
9. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
10. Halozyme Provides HYLENEX® Product Reintroduction Update
11. Halozyme Therapeutics Announces Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... SAN DIEGO , Oct. 20, 2014 /PRNewswire/ ... the availability of the ResMed Data Exchange program, ... for home medical equipment (HME) and other health ... offers timely, secure access to critical patient information. ... from ResMed,s AirView™ and U-Sleep™ patient management platforms ...
(Date:10/20/2014)... Oct. 20, 2014   BioNano Genomics announced today ... ability to collect human data at 30X depth, sufficient for ... This new capability was established and demonstrated for the IrysChip ... TM System and will be rolled out to ... will be showcasing this advancement at the American Society ...
(Date:10/20/2014)... Oct. 20, 2014   Taiho Oncology, Inc. ... ( Japan ), announced that the ... Track designation for TAS-102 (nonproprietary names: trifluridine and ... investigation for the treatment of refractory metastatic colorectal ... a rolling NDA submission to the FDA. According ...
Breaking Medicine Technology:ResMed Launches ResMed Data Exchange 2BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 4
(Date:10/22/2014)... (PRWEB) October 22, 2014 Healthcare ... completing their continuing education at home or on-the-go ... access to 20 brand new, premium Seminar-on-Demand CE ... catalog of over 2,000 hours of ... customize their educational experience. With such a diverse ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Richard Carlson, ... an industry leader with over 25 years experience. ... leader in the areas related to EDI, B2B Commerce, ... is an Editorial Advisory Board member for Pharmaceutical Commerce ... Blue Fin Group is a management and technology ...
(Date:10/22/2014)... sisters in high school have developed ways to measure ... use electronic stethoscopes, which electronically amplify body sounds, to ... heartbeats. Ilina, a senior at Port Huron Northern ... to detect early lung damage in people exposed to ... one breath cycle each from 16 smokers, 25 nonsmokers ...
(Date:10/22/2014)... HealthDay Reporter , MONDAY, Oct. 20, 2014 ... guidelines for health workers treating Ebola patients, now requiring full ... respirator at all times. The U.S. Centers for Disease ... two Dallas nurses contracted Ebola while caring for the first ... Eric Duncan. Nina Pham is currently being treated for her ...
(Date:10/20/2014)... October 20, 2014 Allegheny General Hospital’s ... that enables physicians to repair a damaged mitral valve ... MitraClip system, developed by Abbott Vascular , ... progressive and life-threatening condition in which the heart’s mitral ... flow backward from the heart’s left ventricle into the ...
Breaking Medicine News(10 mins):Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3
... common stock tendered (including guaranteed ... ... a global specialty pharmaceutical company focused on dermatology,today announced that its ... offer for CollaGenex Pharmaceuticals,Inc. (Nasdaq: CGPI ). The tender offer ...
... latest ... at Vitals, LYNDHURST, N.J., April 7, 2008 Vitals.com, a ... announced that Dr. Robert CJ Krasner has agreed to join,Vitals as ... ways to engage doctor participation on the site and aid,Vitals as ...
... expected to increase the bronchoscopy market, to approximately $180 million in ... ... Group, WALTHAM, Mass., April 7, 2008 According to Millennium,Research ... interventional pulmonology -- is creeping into the bronchoscopy,market, and is expected to ...
... Psychotherapist Bob,Livingstone writes about the benefits of ... Solution: Healing Emotional Pain through Exercise" (Pegasus,Books). He ... combines exercise,self-questioning, journaling and listening to music is ... evidence that exercise is just as effective as ...
... 7, 2008 Haemonetics,Corporation (NYSE: HAE ) will announce its Q4FY08 ... 10:00 am (EDT) conference call., Conference Call Dial-In Information ... (973) 935-8754 (International) ID: 42384135 ... pm (EDT). To,access the replay, please dial:, ...
... 26 pounds for just 10 minutes can lead to fatigue, ... -- Wearing a heavy backpack can significantly decrease blood flow ... in the loss of some fine motor skills as well ... wearing backpacks with loads of 26 pounds for just 10 ...
Cached Medicine News:Health News:Galderma Completes Tender Offer for CollaGenex 2Health News:Galderma Completes Tender Offer for CollaGenex 3Health News:Galderma Completes Tender Offer for CollaGenex 4Health News:Dr. Robert CJ Krasner Appointed to Vitals.com as Independent Advisor 2Health News:Interventional Pulmonology Creeping into Bronchoscopy Market 2Health News:The Magnificence of Exercise: Choose Movement Over Medication 2Health News:Tight Backpack Straps Cut Blood to Shoulders, Arms 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: